AMAG AMAG Pharmaceuticals Inc.

8.87
+0.31  (+4%)
Previous Close 8.56
Open 8.42
Price To Book 0.49
Market Cap 299,512,749
Shares 33,766,939
Volume 2,811,936
Short Ratio
Av. Daily Volume 861,645

NewsSee all news

  1. Why Palatin Technologies Stock Dropped as Much as 21.5% Today
  2. How Raleigh's Sprout can benefit from FDA's approval of another female sexual disorder drug
  3. AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire
  4. Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
  5. Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 top-line data due mid-2020.
AMAG-423 / Digoxin immune fab (DIF)
Severe preeclampsia in pregnant women
FDA approval announced June 21, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Approval for sNDA filing announced February 5, 2018.
Feraheme
Adults with iron deficiency anemia (IDA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy
Phase 3b trial did not meet co-primary endpoints - March 8, 2019.
Makena
Preterm birth
Phase 3a trial to be initiated 2H 2019.
Ciraparantag
Anticoagulated reversal agent / Healthy volunteers

Latest News

  1. Why Palatin Technologies Stock Dropped as Much as 21.5% Today
  2. How Raleigh's Sprout can benefit from FDA's approval of another female sexual disorder drug
  3. AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire
  4. Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
  5. Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.
  6. Palatin's stock rockets after FDA OK to market sexual desire disorder treatment
  7. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
  8. AMAG stock rallies on FDA approval for drug to increase women's sex drive
  9. Amag’s plan to bypass female libido drug pitfalls? Social media.
  10. AMAG Pharmaceuticals Announces FDA Approval of Vyleesi™ (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
  11. All You Need to Know About AMAG Pharmaceuticals (AMAG) Rating Upgrade to Buy
  12. TherapeuticsMD Enters Agreement to Market Drugs Outside US
  13. AMAG Pharmaceuticals (AMAG) Down 8.9% Since Last Earnings Report: Can It Rebound?
  14. AMAG Pharmaceuticals Could Be Cut in Half Even From Here - Avoid
  15. AMAG Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
  16. Is AMAG Pharmaceuticals, Inc.'s (NASDAQ:AMAG) Balance Sheet A Threat To Its Future?
  17. New Strong Sell Stocks for May 20th
  18. AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York
  19. Edited Transcript of AMAG earnings conference call or presentation 7-May-19 12:00pm GMT